| Ytd | 13.51% | |
| 1y | -28.36% |
| Open | 0.87 | Prev Close | 0.88 | Low | 0.86 | High | 0.90 | Mkt Cap | 48.78M |
| Vol | 190.43K | Avg Vol | 1.03M | EPS | -0.66 | P/E | N/A | Forward P/E | -1.18 |
| Beta | 1.93 | Short Ratio | 10.47 | Inst. Own | 12.36% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.06 | 200-d Avg | 0.92 | 1yr Est | 11.50 |
PDSB News
Up to $50,000,000 Common StockWe have entered into the sales agreement (the "Sales Agreement"
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analys
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with
PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal can
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analys
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late
Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34
https://www.sec.gov/ix?doc=/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm#fact-id
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a lat
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovat
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a lat
New Patent Grants Broad Composition Claims for PDS0101Previously Granted Patent Protections and Anti
B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.19) per share which beat the analys
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late
Translational study shows that multiple immunological biomarkers predict the clinical activity of PD
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a lat
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a lat
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care K
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with s
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.21) per share which beat the analys
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapi
Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentationPRINCETO
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(1.03) per share which beat the analys